GET DAILY SIGNALSNUTX Delivers Strong 2025 Growth Despite Q4 Revenue Reset
Key Takeaways
- Nutex Health reported full-year 2025 revenue of $875.3 million, an 82% increase from $479.9 million in 2024.
- Fourth quarter 2025 revenue fell 41.1% year over year to $151.7 million, driven by a one-time $55 million revenue reduction tied to an arbitration claims true-up.
- Net income attributable to Nutex Health reached $70.8 million for 2025, up from $52.1 million in the prior year.
- Full-year Adjusted EBITDA climbed 152.6% to $259.6 million.
- Total patient visits rose 11.8% to 188,300, while cash and cash equivalents surged to $185.6 million from $40.6 million a year earlier.
- The company authorized a second $25 million stock repurchase program and reported $248.1 million in operating cash flow for the year.
Putting the Results in Context
NUTX, a Houston-based operator of micro-hospitals and hospital outpatient departments across 12 states, wrapped up 2025 with notable gains in revenue, profitability, and cash generation. Its reimbursement approach leans heavily on the Independent Dispute Resolution process to address insurer underpayments under the No Surprises Act. That structure produced strong annual figures, yet it also led to a sizable one-time accounting adjustment in the fourth quarter when a backlog of arbitration claims was reconciled. In my view, this report is worth close attention because it shows whether investors can distinguish a single-quarter technical reset from the underlying momentum of a growing, cash-rich healthcare platform.
Breaking Down the Reported Numbers
For the fourth quarter ended December 31, 2025, NUTX posted total revenue of $151.7 million, down 41.1% from $257.6 million in the prior-year quarter. The drop included a one-time, roughly $55 million revenue reduction tied to a cumulative true-up of about 18,950 arbitration claims deemed ineligible under the IDR process after a mid-2025 CMS directive. Net income attributable to Nutex Health came in at $11.8 million for the quarter, compared with $61.6 million a year earlier, while Adjusted EBITDA fell to $16.6 million from $86.7 million.
Full-year results painted a clearer picture of progress. Revenue reached $875.3 million, up 82% from $479.9 million in 2024. Net income attributable to Nutex Health rose to $70.8 million from $52.1 million, and Adjusted EBITDA increased 152.6% to $259.6 million. Total patient visits grew 11.8% to 188,300. Operating cash flow for the year was $248.1 million, versus $23.2 million in 2024, and the company finished the year with $185.6 million in cash and cash equivalents. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Consensus expectations ahead of the report had pointed to fourth-quarter revenue near $249.5 million, so the $151.7 million result stood out as a shortfall. Management presented the decline as a one-time, non-cash reconciliation rather than any operational weakness, noting that excluding the $55 million adjustment would have left adjusted fourth-quarter revenue around $206.7 million, more in line with earlier quarters. Investors appeared to balance the solid annual results, strong cash generation, and the new $25 million buyback authorization against the quarterly revenue reset. The stock reaction likely depended on how much weight the market gave to full-year and cash-flow performance over the lumpy fourth-quarter accounting impact.
What to Watch Going Forward
Several elements will influence sentiment around NUTX in the periods ahead. The resolution of the IDR true-up stands out as one key variable. Management noted that consultants are challenging ineligibility determinations for some disputed claims, and favorable outcomes could bring revenue back in future quarters.
The path of the arbitration process itself also merits attention. The company routes a large share of claims through IDR, securing favorable determinations on more than 85% of decided cases with a cash collection rate above 85%. Any changes in federal rules around the No Surprises Act or the IDR framework could affect reimbursement economics going forward.
Expansion and capital allocation remain important as well. Nutex Health opened three new facilities in 2025 and early 2026 and maintains a pipeline of additional hospitals, while its second $25 million repurchase program reflects management’s view on intrinsic value. Tracking visit growth, revenue per patient, and the contribution from mature hospitals as new sites ramp up will be useful.
Finally, the $185.6 million cash position and low operating debt offer flexibility, though the $319.4 million accounts receivable balance will be monitored for collection trends. These factors together will help determine whether the 2025 momentum continues into 2026.
Using AI Tools for Deeper Analysis
When I want to scan for comparable names or refine ideas in the healthcare sector, Tickeron’s AI Screener gives me a practical way to apply technical patterns, fundamentals, and performance filters across thousands of stocks and ETFs. It helps surface potential opportunities more efficiently than manual reviews and has become a regular part of how I cross-check sector trends.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
NUTX's Indicator enters downward trend
The Aroon Indicator for NUTX entered a downward trend on November 04, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 210 similar instances where the Aroon Indicator formed such a pattern. In 195 of the 210 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for NUTX turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 35 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
The 10-day moving average for NUTX crossed bearishly below the 50-day moving average on November 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NUTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NUTX's RSI Indicator exited the oversold zone, 24 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on NUTX as a result. In 81 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
NUTX moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +6.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where NUTX advanced for three days, in 218 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
NUTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 19 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. NUTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.363) is normal, around the industry mean (204.059). P/E Ratio (7.228) is within average values for comparable stocks, (18.581). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.091) among similar stocks. P/S Ratio (1.830) is also within normal values, averaging (2.688).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NUTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement
Advertisement